339
Views
8
CrossRef citations to date
0
Altmetric
Brief Report

Safety and tolerability of brimonidine purite 0.1% and brimonidine purite 0.15%: a meta-analysis of two phase 3 studies

, , &
Pages 1615-1620 | Accepted 27 Apr 2009, Published online: 26 May 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Mamun Q Rahman, Kanna Ramaesh & Donald MI Montgomery. (2010) Brimonidine for glaucoma. Expert Opinion on Drug Safety 9:3, pages 483-491.
Read now

Articles from other publishers (7)

Nupur Vasdev, Nakshatra Chaudhari, Suryanarayana Polaka, Kuldeep Rajpoot, Piyush Gondaliya, Adil Ali Sayyed, Pinaki Sengupta & Rakesh Kumar Tekade. (2023) Current progress in preservative-free topical ophthalmic formulations. Journal of Drug Delivery Science and Technology 79, pages 103996.
Crossref
Yuko Maruyama, Yoko Ikeda, Norihiko Yokoi, Kazuhiko Mori, Hiroaki Kato, Morio Ueno, Shigeru Kinoshita & Chie Sotozono. (2017) Severe Corneal Disorders Developed After Brimonidine Tartrate Ophthalmic Solution Use. Cornea 36:12, pages 1567-1569.
Crossref
Alex S. Huang, Lilit Minasyan & Robert N. Weinreb. 2017. Pharmacologic Therapy of Ocular Disease. Pharmacologic Therapy of Ocular Disease 181 207 .
Deepak Sambhara & Ahmad A. Aref. (2013) Glaucoma management: relative value and place in therapy of available drug treatments. Therapeutic Advances in Chronic Disease 5:1, pages 30-43.
Crossref
Stella Arthur & Louis B. Cantor. (2011) Update on the role of alpha-agonists in glaucoma management. Experimental Eye Research 93:3, pages 271-283.
Crossref
Gabi Shemesh, Elad Moisseiev, Moshe Lazar & Anat Kesler. (2011) Effect of brimonidine tartrate 0.10% ophthalmic solution on pupil diameter. Journal of Cataract and Refractive Surgery 37:3, pages 486-489.
Crossref
. (2010) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 19:2.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.